:max_bytes(150000):strip_icc()/GettyImages-2280950735-c28c1251aea04f9a8e575484938793f8.jpg?#)
These three Pharma stocks should be on your radar today; Key factors explained
Ajanta Pharma inked an in-licensing agreement with Biocon Ltd. for semaglutide, a GLP-1 receptor agonist. Zydus Lifesciences Ltd. has partnered with Swiss biopharmaceutical firm Bioeq AG to license, supply and commercialise NUFYMCO, an interchangeable biosimilar to Lucentis (ranibizumab) in the US market. Emcure Pharma has received an EIR from the US drug regulator for with a 'no action indicated' (NAI) for its facility in Gujarat.
Ajanta Pharma inked an in-licensing agreement with Biocon Ltd. for semaglutide, a GLP-1 receptor agonist. Zydus Lifesciences Ltd. has partnered with Swiss biopharmaceutical firm Bioeq AG to license, supply and commercialise NUFYMCO, an interchangeable biosimilar to Lucentis (ranibizumab) in the US market. Emcure Pharma has received an EIR from the US drug regulator for with a 'no action indicated' (NAI) for its facility in Gujarat.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
